This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

William E. Hathaway, MD

Am J Dis Child. 1984;138(3):301-304.

Abstract
• Many diseases in children are associated with thrombotic tendencies either as a complication or as part of the patho-physiologic process. Disorders in which platelet consumption and/or activation occur incude myeloproliferative syndromes, sickle cell disease, cardiac prostheses, arteriovenous shunts, vasculitis, diabetes mellitus, and hemolytic-uremic syndrome and other renal diseases. Platelet involvement can be demonstrated by several indicators, including an increase in platelet release product levels in the plasma (β-thromboglobulin, platelet factor 4, and thromboxane B₂). The agents that have the greatest success in thrombotic disorders where platelet involvement is prominent include the prostaglandin pathway cyclo-oxygenase inhibitors aspirin and sulfinpyrazone, as well as dipyridamole. Although indications and dosages for the use of antiplatelet agents in children can be suggested, the treatment of each patient should be individualized in light of current knowledge.

(AJDC 1984;138:301-304)

Author Affiliations
From the Department of Pediatrics, University of Colorado School of Medicine, Denver.

Footnotes
Reprint requests to Department of Pediatrics, University of Colorado School of Medicine, 4200 E Ninth Ave (C-220), Denver, CO 80262 (Dr Hathaway).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Antithrombotic Therapy in Children
Monagle et al.
Chest 2001;119 :344S-370S.
FULL TEXT